Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma is a phase 3 interventional study registered as NCT06792253, led by BeBetter Med, and recruiting on the registry. Official title: Phase Ⅲ Clinical Trial Comparing BEBT-908 Combined With Rituximab (R) to Standard of Care for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Planned enrolment is 416 participants (estimated). The study started in 2025-01-06 and primary completion is expected in 2028-12-31. No results have been posted on ClinicalTrials.gov.